This risk estimate for TP53 mutations (OR = 8.17, 95% CI 3.74–18.26) has substantially tighter confidence intervals than previously reported risk estimates (OR = 11, 95% CI 0.6−201).14 However, further studies providing functional and risk associated annotation of variants, and accounting for contamination of true germline TP53 mutations with mosaic mutations that arise due to clonal hematopoiesis,27 are needed to define accurate risk estimates for breast cancer associated with TP53 inactivating mutations. The gene discussed is TP53; the disease is breast carcinoma.